Motif Bio PLC Director/PDMR Shareholding (4111U)
January 18 2017 - 1:05AM
UK Regulatory
TIDMMTFB
RNS Number : 4111U
Motif Bio PLC
18 January 2017
18 January 2017
Motif Bio plc
("Motif Bio" or the "Company")
Grant of share options to PDMR
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that the Company has granted a total of 1,500,000 options to
purchase ordinary shares of 1 pence each of Motif Bio ("Ordinary
Shares") to Robert Dickey IV, Chief Financial Officer. The options
vest over a four year period and have an exercise price of 25.5
pence per Ordinary Share, being the closing price of the Ordinary
Shares on 17 January 2017, the date of grant of the options.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
1 Details of the person discharging managerial responsibilities/person closely associated
------ -----------------------------------------------------------------------------------------------
a) Name Robert Dickey IV
------ ------------------------------------------ ---------------------------------------------------
2 Reason for the notification
------ -----------------------------------------------------------------------------------------------
Chief Financial Officer, PDMR
a) Position/status
------ ------------------------------------------ ---------------------------------------------------
b) Initial notification/Amendment Initial Notification
------ ------------------------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
------ -----------------------------------------------------------------------------------------------
a) Name Motif Bio Plc
------ ------------------------------------------ ---------------------------------------------------
b) LEI 54930080DN00QTIUUU84
------ ------------------------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
------ -----------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument ISIN GB00BVVT4H71
Identification code
------ ------------------------------------------ ---------------------------------------------------
b) Nature of the transaction Grant of options to purchase 1,500,000
Ordinary Shares
------ ------------------------------------------ ---------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 1,500,000
---------- ----------
------ ------------------------------------------ ---------------------------------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 1,500,000
---------- ----------
------ ------------------------------------------ ---------------------------------------------------
e) Date of the transaction 17 January 2017
------ ------------------------------------------ ---------------------------------------------------
f) Place of the transaction N/A
------ ------------------------------------------ ---------------------------------------------------
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Zeus Capital Limited (NOMAD
& BROKER)
Phil Walker/Giles Balleny
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/David
Hignell
John Howes/Rob Rees (Broking) +44 (0)20 7382 1100
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials (Revive 1 and Revive 2) with an
intravenous formulation of iclaprim, for the treatment of ABSSSI.
Data readout for REVIVE-1 is expected in the second quarter of 2017
and REVIVE-2 is on track for data readout in the second half of
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAEFXFFDXEAF
(END) Dow Jones Newswires
January 18, 2017 02:05 ET (07:05 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024